Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders (MGDs)—small molecule drugs that leverage the body's natural protein destruction machinery to selectively eliminate disease-causing proteins. The company's proprietary QuEEN™ discovery platform combines artificial intelligence, high-throughput screening, structural biology, and proteomics to identify and design MGDs targeting proteins traditionally considered undruggable by conventional drug modalities, drawing from a library of tens of thousands of distinct molecules. Monte Rosa generates revenue through upfront partnership payments, milestone achievements tied to drug development and regulatory approval, royalties on drug sales, and profit-sharing arrangements with pharmaceutical collaborators; its pipeline spans immune-mediated diseases, inflammatory conditions, and oncology indications, with programs in clinical development and others licensed to major partners.